REFERENCES
- Dhillon S. Carotegrast Methyl: First Approval. Drugs .
2022;82(9):1011-6. doi: 10.1007/s40265-022-01732-0.
- Sugiura T, Kageyama S, Andou A, et al. Oral treatment with a novel
small molecule alpha 4 integrin antagonist, AJM300, prevents the
development of experimental colitis in mice. J Crohns Colitis .
2013;7(11):e533-42. doi: 10.1016/j.crohns.2013.03.014.
- Yoshimura N, Watanabe M, Motoya S, et al. Safety and efficacy of
AJM300, an oral antagonist of α4 integrin, in induction therapy for
patients with active ulcerative colitis. Gastroenterology .
2015;149(7):1775-83.e2. doi: 10.1053/j.gastro.2015.08.044.
- Matsuoka K, Watanabe M, Ohmori T, et al. AJM300 (carotegrast methyl),
an oral antagonist of α4-integrin, as induction therapy for patients
with moderately active ulcerative colitis: a multicentre, randomised,
double-blind, placebo-controlled, phase 3 study. Lancet
Gastroenterol Hepatol . 2022;7(7):648-57. doi:
10.1016/S2468-1253(22)00022-X.
- Bloomgren G, Richman S, Hotermans C, et al. Risk of
natalizumab-associated progressive multifocal leukoencephalopathy.N Engl J Med . 2012;366(20):1870-80. doi: 10.1056/NEJMoa1107829.
- McGuigan C, Craner M, Guadagno J, et al. Stratification and monitoring
of natalizumab-associated progressive multifocal leukoencephalopathy
risk: recommendations from an expert group. J Neurol Neurosurg
Psychiatry . 2016;87(2):117-25. doi: 10.1136/jnnp-2015-311100.
- Williamson EML, Berger JR. Diagnosis and Treatment of Progressive
Multifocal Leukoencephalopathy Associated with Multiple Sclerosis
Therapies. Neurotherapeutics . 2017;14(4):961-73. doi:
10.1007/s13311-017-0570-7.
- Fukase H, Kajioka T, Oikawa I, Ikeda N, Furuie H. Food effect on a
single high dose of carotegrast methyl, an oral antagonist of
α4-integrin, in healthy male subjects: a randomised,
placebo-controlled, double-blind study. Clin Drug Investig .
2020;40(3):237-47. doi: 10.1007/s40261-019-00879-1.
- Fukase H, Kajioka T, Oikawa I, Ikeda N, Furuie H. AJM300, a novel oral
antagonist of α4-integrin, sustains an increase in circulating
lymphocytes: A randomised controlled trial in healthy male subjects.Br J Clin Pharmacol . 2020;86(3):591-600. doi:
10.1111/bcp.14151.
- Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative
colitis. Lancet . 2012;380(9853):1606-19. doi:
10.1016/S0140-6736(12)60150-0.
- Feuerstein JD, Cheifetz AS. Ulcerative colitis: epidemiology,
diagnosis, and management. Mayo Clin Proc . 2014;89(11):1553-63.
doi: 10.1016/j.mayocp.2014.07.002.
- Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF.
Ulcerative colitis. Lancet . 2017;389(10080):1756-70. doi:
10.1016/S0140-6736(16)32126-2.
- Ministry of Health, Labour and Welfare, Guideline on drug interaction
for drug development and appropriate provision of information.
https://www.pmda.go.jp/files/000228122.pdf. Accessed April 8, 2023.
- Foti RS, Rock DA, Wienkers LC, Wahlstrom JL. Selection of alternative
CYP3A4 probe substrates for clinical drug interaction studies using in
vitro data and in vivo simulation. Drug Metab Dispos .
2010;38(6):981-7. doi: 10.1124/dmd.110.032094.
- Denisov IG, Grinkova YV, Camp T, McLean MA, Sligar SG. Midazolam as a
Probe for Drug-Drug Interactions Mediated by CYP3A4: Homotropic
Allosteric Mechanism of Site-Specific Hydroxylation.Biochemistry . 2021;60(21):1670-81. doi:
10.1021/acs.biochem.1c00161.
- Denisov IG, Grinkova YV, McLean MA, Camp T, Sligar SG. Midazolam as a
Probe for Heterotropic Drug-Drug Interactions Mediated by CYP3A4.Biomolecules . 2022;12(6):853. doi: 10.3390/biom12060853.
- Thummel KE, O’Shea D, Paine MF, et al. Oral first-pass elimination of
midazolam involves both gastrointestinal and hepatic CYP3A-mediated
metabolism. Clin Pharmacol Ther . 1996;59(5):491-502. doi:
10.1016/S0009-9236(96)90177-0.
- Steenholdt C, Jensen JT, Brynskov J, et al. Patient satisfaction of
propofol versus midazolam and fentanyl sedation during colonoscopy in
inflammatory bowel disease. Clin Gastroenterol Hepatol .
2022;20(3):559-68.e5. doi: 10.1016/j.cgh.2020.10.037.
- Nakase H, Uchino M, Shinzaki S, et al. Evidence-based clinical
practice guidelines for inflammatory bowel disease 2020. J
Gastroenterol . 2021;56(6):489-526. doi: 10.1007/s00535-021-01784-1.
- Varis T, Kivistö KT, Neuvonen PJ. The effect of itraconazole on the
pharmacokinetics and pharmacodynamics of oral prednisolone. Eur
J Clin Pharmacol . 2000;56(1):57-60. doi: 10.1007/s002280050720.
- Lebrun-Vignes B, Archer VC, Diquet B, et al. Effect of itraconazole on
the pharmacokinetics of prednisolone and methylprednisolone and
cortisol secretion in healthy subjects. Br J Clin Pharmacol .
2001;51(5):443-50. doi: 10.1046/j.1365-2125.2001.01372.x.
- Skauby RH, Bergan S, Andersen AM, Vethe NT, Christensen H. In vitro
assessments predict that CYP3A4 contributes to a greater extent than
CYP3A5 to prednisolone clearance. Basic Clin Pharmacol Toxicol .
2021;129(6):427-36. doi: 10.1111/bcpt.13645.
- Lennernäs H. Clinical pharmacokinetics of atorvastatin. Clin
Pharmacokinet . 2003;42(13):1141-60. doi:
10.2165/00003088-200342130-00005.
- Molden E, Skovlund E, Braathen P. Risk management of simvastatin or
atorvastatin interactions with CYP3A4 inhibitors. Drug Saf .
2008;31(7):587-96. doi: 10.2165/00002018-200831070-00004.
- Hirota T, Fujita Y, Ieiri I. An updated review of pharmacokinetic drug
interactions and pharmacogenetics of statins. Expert Opin Drug
Metab Toxicol . 2020;16(9):809-22. doi: 10.1080/17425255.2020.1801634.
- Ohno Y, Hisaka A, Suzuki H. General framework for the quantitative
prediction of CYP3A4-mediated oral drug interactions based on the AUC
increase by coadministration of standard drugs. Clin
Pharmacokinet . 2007;46(8):681-96. doi:
10.2165/00003088-200746080-00005.
- Ohno Y, Hisaka A, eds. Pharmacokinetic Drug Interaction Management:
Basics and Practice of PISCS, 2nd Edit. Tokyo, Japan: Jiho, Inc.;
2021. Japanese.
- Imai H, Kotegawa T, Tsutsumi K, et al. The recovery time-course of
CYP3A after induction by St John’s wort administration. Br J
Clin Pharmacol . 2008;65(5):701-7. doi:
10.1111/j.1365-2125.2008.03120.x.
- Interview form of Lipitor ® Tablets 5mg/10mg issued on April 2014.
https://www.info.pmda.go.jp/go/interview/2/671450_2189015F1023_2_1F.pdf.
Japanese. Accessed April 9, 2023.
- Cannady EA, Suico JG, Wang MD, et al. CYP-mediated drug-drug
interactions with evacetrapib, an investigational CETP inhibitor: in
vitro prediction and clinical outcome. Br J Clin Pharmacol .
2015;80(6):1388-98. doi: 10.1111/bcp.12730.
- Skauby RH, Bergan S, Andersen AM, Vethe NT, Christensen H. In vitro
assessments predict that CYP3A4 contributes to a greater extent than
CYP3A5 to prednisolone clearance. Basic Clin Pharmacol Toxicol .
2021;129(6):427-36. doi: 10.1111/bcpt.13645.
- Kantola T, Kivistö KT, Neuvonen PJ. Effect of itraconazole on the
pharmacokinetics of atorvastatin. Clin Pharmacol Ther .
1998;64(1):58-65. doi: 10.1016/S0009-9236(98)90023-6.